Levosimendan Improves Renal Function in Patients With Advanced Chronic Heart Failure Awaiting Cardiac Transplantation

Journal of Cardiac Failure

Volumn 13, Issue 6, 2007, Pages 417-421

  Zemljic, Gregor ^a   Bunc, Matjaz ^a   Yazdanbakhsh, Aria P ^b   Vrtovec, Bojan ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Heart failure; heart transplantation; renal function

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEVOSIMENDAN; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CREATININE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; PYRIDAZINES; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 34547442389     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.03.005     Document Type: Article

References (21)

1. Smith G.L., Shlipak M.G., Havranek E.P., et al. Race and renal impairment in heart failure: Mortality in black versus whites. Circulation 111 (2005) 1270-1277
2. Hillege H.L., Nitsch D., Pfeffer M.A., et al., on behalf of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
3. Hillege H.L., Girbes A.R.J., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
4. Vossler M.R., Ni H., Toy W., and Hershberger R.E. Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 21 (2002) 874-881
5. Odim J., Wheat J., Laks H., et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 162-166
6. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised, double-blind trial. Lancet 360 (2002) 196-202
7. Cleland J.G., Freemantle N., Coletta A.P., et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
8. Swedberg K., Cleland J., Dargie H., et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
9. Costanzo M.R., Augustine S., Bourge R., et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92 (1995) 3593-3612
10. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of WRF in congestive heart failure. J Card Fail 8 (2002) 136-141
11. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of WRF with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
12. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102 (2000) 2222-2227
13. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., and Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9 (2007) 75-82
14. McLean A.S., Huang S.J., Nalos M., and Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 46 (2005) 830-835
15. Pagel P., Hettrick D., and Warltier D. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 119 (1996) 609-615
16. Oldner A., Konrad D., Weitzberg E., Rudehill A., Rossi P., and Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 29 (2001) 2185-2193
17. Faivre V., Kaskos H., Callebert J., et al. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology 103 (2005) 514-521
18. Zager R.A., Johnson A.C., Lund S., Hanson S.Y., and Abrass C.K. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 290 (2006) F1453-F1462
19. Kivikko M., and Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 11 (2005) 435-455
20. Parissis J.T., Adamopoulos S., Antoniades C., et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309-1312
21. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92